Just a moment, the page is loading...

*EISAI-E7080-G000-303




A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
lenvatinib
E7080-G000-303
NCT01321554
EU CTR 2010-023783-41
Thyroid Cancer
Phase 3
 
Sharing of clinical data is prevented for the following countries; Germany, France, Sweden, Poland, due to ICF restrictions.
August 2015